Saturday 17 October 2026
Export HLN’s income statement to Excel — free account
Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.
10.13
0.19
+1.91%
Follow HLN
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 8 | 8 |
P/E ratio |
20.41 | 20.41 | 20.41 | 20.41 | 20.41 | 21.27 | 22.54 |
Altman Z-Score |
— | — | — | 2.53 | 2.72 | 2.78 | 3.04 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.42 | 2.57 |
Altman Z″-Score (non-manufacturers) |
4.86 | 7.98 | — | 3.74 | 4.07 | 3.95 | 4.27 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.39 | 9.02 |
Beneish M-Score |
— | (2.59) | — | — | (2.61) | (2.52) | (2.60) |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend Safety Score |
— | — | — | — | — | — | 66 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 1.83 | 2.08 | 2.18 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.14 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.79 | 13.39 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.06 | 9.61 |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.64 | 11.04 |
Quick Ratio |
1.02 | 0.99 | 1.01 | 0.61 | 0.64 | 0.76 | 0.70 |
Current Ratio |
1.36 | 1.25 | 1.24 | 0.93 | 1.04 | 0.98 | 0.92 |
Net Debt/EBITDA |
0.15 | 0.07 | 0.26 | 4.62 | 3.65 | 3.11 | 2.63 |
Debt/Assets |
1.80% | 1.43% | 0.00% | 29.99% | 27.77% | 29.51% | 26.38% |
Debt/Equity |
0.02 | 0.02 | 0.04 | 0.63 | 0.57 | 0.62 | 0.52 |
Asset Turnover |
0.00 | 0.29 | 0.55 | 0.30 | 0.33 | 0.33 | 0.33 |
Operating CF/Net income |
1.19 | 1.23 | 0.98 | 1.95 | 2.00 | 1.60 | 1.58 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (1.02) | (0.29) | 0.02 | (1.15) |
Interest Coverage |
82.43 | 106.53 | 300.46 | 7.07 | 4.97 | 5.74 | 7.09 |
| 0.00% | 4.37% | 5.26% | 4.69% | 6.34% | 8.87% | 10.35% | |
| 0.00% | 3.35% | 8.04% | 2.92% | 3.06% | 4.27% | 5.06% | |
ROIC |
0.00% | 0.00% | 0.00% | 4.35% | 4.96% | 5.72% | 6.34% |
Return on Tangible Assets |
20.71% | 44.11% | 51.96% | 73.31% | 53.58% | 84.08% | 112.03% |
Average Days of Receivables |
173.16 | 134.72 | 148.41 | 66.46 | 62.88 | 69.80 | 70.25 |
Research and Development Expense of Revenue |
3.44% | 3.07% | 2.69% | 2.76% | 2.75% | 2.65% | 2.86% |
Selling, General and Administrative Expense of Revenue |
32.77% | 38.36% | 39.18% | 41.29% | 39.05% | 39.63% | 39.56% |
Intangible Assets out of Total Assets |
0.78 | 0.80 | 0.00 | 0.82 | 0.79 | 0.76 | 0.79 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.67% | 0.91% | 0.78% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | (0.44) | (0.34) | (0.34) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
4.90% | 4.90% | 4.90% | 4.90% | 4.90% | 4.70% | 4.44% |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.65% | 11.09% |
Revenue per Share |
2.41 | 2.93 | 2.79 | 2.91 | 3.05 | 3.14 | 3.24 |
Operating CF per Share |
0.22 | 0.42 | 0.40 | 0.55 | 0.57 | 0.64 | 0.77 |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.08) | (0.02) | 0.00 | (0.12) |
Free Cash Flow per Share |
0.22 | 0.42 | 0.40 | 0.47 | 0.54 | 0.65 | 0.65 |
Cash per Share |
0.10 | 0.10 | 0.12 | 0.18 | 0.28 | 0.63 | 0.39 |
Shareholders Equity per Share |
7.78 | 7.74 | 7.71 | 4.41 | 4.51 | 4.54 | 4.84 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.78 | 7.74 | 7.71 | 4.41 | 4.51 | 4.54 | 4.84 |
Free Cash Flow |
1,027.63 | 1,927.40 | 1,833.78 | 2,190.55 | 2,500.24 | 2,949.39 | 2,928.83 |
Working Capital |
2,028.95 | 1,361.64 | 1,368.92 | (384.68) | 221.41 | (120.12) | (505.06) |
Capital Expenditures |
(319.74) | (435.62) | (402.70) | (361.17) | (111.95) | 8.95 | (544.62) |
Net Current Asset Value |
(3,273.68) | (3,971.23) | (3,675.68) | (17,686.43) | (15,558.70) | (15,811.46) | (15,291.64) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.75 | 17.53 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.00 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.51 | 14.32 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.16 | 0.19 | 0.16 | 0.16 | 0.17 | 0.18 | 0.19 |
Cash ROIC |
2.76% | 5.22% | 4.89% | 6.42% | 7.38% | 8.07% | 8.41% |
Accounts Receivable Turnover |
0.00 | 2.63 | 2.52 | 3.49 | 5.78 | 5.56 | 5.25 |
Accounts Payable Turnover |
0.00 | 3.19 | 2.64 | 1.67 | 1.28 | 1.24 | 1.08 |
Inventory Turnover |
0.00 | 3.77 | 3.76 | 3.59 | 3.31 | 3.44 | 3.63 |
Average Days of Payables |
119.19 | 122.83 | 138.99 | 308.73 | 282.54 | 306.72 | 344.67 |
Days of Inventory on Hand |
120.18 | 86.99 | 96.55 | 114.93 | 112.83 | 98.51 | 94.72 |
Average Receivables |
— | 5,147.40 | 5,122.98 | 3,844.97 | 2,433.61 | 2,583.40 | 2,772.26 |
Average Payables |
— | 1,707.94 | 1,842.81 | 3,164.41 | 4,432.40 | 4,560.31 | 4,826.69 |
Average Inventory |
— | 1,446.71 | 1,292.57 | 1,476.24 | 1,709.38 | 1,636.06 | 1,436.18 |
Average Assets |
— | 46,870.79 | 23,376.71 | 44,908.05 | 42,711.85 | 43,106.08 | 43,440.16 |
Average Common Equity |
— | 35,859.27 | 35,692.36 | 27,985.26 | 20,582.43 | 20,770.93 | 21,235.05 |
Columns are period end dates